Artivion AMDS Prosthesis FDA Approval
Analysis based on 6 articles · First reported Jun 29, 2026 · Last updated Jun 29, 2026
The PMA approval of the AMDS Hybrid Prosthesis by the United States — Food and Drug Administration is a significant positive for Artivion, as it removes administrative hurdles for hospitals and is expected to accelerate the adoption of this life-saving technology. This could lead to increased revenue and market share for Artivion in the cardiac and vascular surgery market. Artivion's shares saw an initial rise in pre-market trading following the announcement.
Artivion, a cardiac and vascular surgery company, announced that the United States — Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for its AMDS Hybrid Prosthesis. This device is the world's first aortic arch remodeling device for treating acute DeBakey Type I aortic dissections. The approval, based on data from the PERSEVERE U.S. IDE trial, demonstrated significant reductions in mortality and major adverse events. The PMA eliminates the need for institutional review board (IRB) approval, reducing administrative burden on hospitals and enabling broader and more immediate patient treatment across U.S. institutions. This approval positions Artivion to fully penetrate an estimated $150 million annual U.S. market opportunity, strengthening its portfolio of aortic arch solutions.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard